EMQN
The European Molecular Genetics Quality Network

4367
UKAS Accredited Proficiency Testing Provider

EMQN Office
Manchester Centre for Genomic Medicine,
6th Floor, St Mary's Hospital, Hathersage Road,
Manchester M13 9WL, United Kingdom.
Tel: +44 161 276 6741
Fax: +44 161 276 6606
Email: office@emqn.org

INDIVIDUAL LABORATORY REPORT (ILR) - Lab 1678

SCHEME: HBOC (Panel Testing) **SEASON:** 2021

Case 1		
Assessment Category	**Score[1]**	**Comments (& deductions[2])**
Genotyping	2.00	No deduction (0.00)
Interpretation	2.00	No deduction (0.00)
Patient Identifiers and Clerical Accuracy	2.00	No deduction (0.00)

Case 2		
Assessment Category	**Score[1]**	**Comments (& deductions[2])**
Genotyping	2.00	No deduction (0.00)
Interpretation	2.00	No deduction (0.00)
Patient Identifiers and Clerical Accuracy	2.00	Incorrect or no pagination (eg X of Y) (0.00)

Case 3		
Assessment Category	**Score[1]**	**Comments (& deductions[2])**
Genotyping	2.00	No deduction (0.00)
Interpretation	1.50	There is no conclusive evidence for RAD50 causing an increased risk of breast/ovarian cancer. See Hu et al. 2018, Dorling et al 2021, LaDuca et al. 2020 for the large studies (0.00) Comment with deduction (0.50) Given the controversial RAD50 variant it is imperative that you recommend your patient receive genetic counselling.
Patient Identifiers and Clerical Accuracy	2.00	Incorrect or no pagination (eg X of Y) (0.00)

[1] Maximum score is 2.00
[2] Deductions from the maximum score
[3] Green >= Scheme mean, Orange < Scheme mean, Red Poor performance.
NRS no results submitted. WDS withdrew from scheme

Published: 20 October 2021

General Comments	Genetic counselling is recommended for patients and their family members whenever a variant is identified. Thank you for participating in this year's EQA scheme. We look forward to you joining us again in 2022.

Appeal response	
Decision	Partially Upheld
Comments	Appeals decision on Marking: Case 3, interpretation: Marks not returned: Feedback: We agree that you have stated that their is no evidence for the clinical relevance for RAD50, and the follow up recommendations are correct. However it is still included as pathogenic which is confusing. Appeals decision on Marking: Cases 1 and 2, interpretation: Marks returned: Feedback: 0.5 marks returned for Counselling and/or follow up is relevant but not mentioned in report. Acknowledge mention of surveillance however ideally genetic counseling should also be mentioned. Deduction was for lack of counseling. Strongly recommend for next year. We appreciate your comment on the Lynch panel as we are working towards ensuring all panels are marked equivalently.

SUMMARY OF YOUR PERFORMANCE IN THIS SCHEME

Assessment Category	**Performance**[3] (mean score)
Genotyping	**2.00**
Interpretation	**1.83**
Patient Identifiers and Clerical Accuracy	**2.00**
Scheme result (SATISFACTORY or POOR)	**SATISFACTORY**

Report approved and authorised by Simon Patton (20 October 2021) on behalf of EMQN.
Signed:

[1] Maximum score is 2.00
[2] Deductions from the maximum score
[3] Green >= Scheme mean, Orange < Scheme mean, Red Poor performance.
NRS no results submitted. WDS withdrew from scheme

Published: 20 October 2021